Repertoire Immune Medicines’ Post

Welcoming researchers to submit manuscripts related to vaccine formulation and delivery in the Scientific Reports Vaccine delivery Collection! Vaccines are great tools to reduce infectious disease transmission and severe disease outcome. The best vaccines provide good protection with minimal side-effects. However, balancing between vaccine efficacy and safety can be challenging, as the immune responses responsible for vaccine protection may also be involved in adverse events outcome. In this special edition, we hope to invite scientists to submit research or review articles related to vaccine formulation and delivery, including vaccine delivery strategies that can either improve vaccine efficacy or reduce occurrence of side effects. For more information, you may click the link as detailed in the comments section. You may also reach out to me if you have any other questions! #vaccines #vaccineswork #research

Bavarian Nordic’s rapid response to the mpox outbreaks underscores the critical importance of agile vaccine development and manufacturing capabilities in addressing emerging global health threats. The ability to scale production quickly and engage in strategic partnerships, such as with the Africa CDC, highlights the evolving landscape of global health preparedness. As we continue to face unpredictable health challenges, it’s essential for the industry to prioritise flexible, context-driven solutions that ensure timely and equitable access to vaccines across all regions, particularly in vulnerable areas like Africa.

Rubella, or German measles, used to be a prevalent disease in the United States – one that posed particular risk to children through congenital rubella syndrome. However, thanks to collaborative research from The Wistar Institute, a vaccine for rubella – co-administered with the vaccines for mumps and measles – has drastically reduced the number of cases, to the point that it is no longer considered endemic in the U.S. All told, the MMR vaccine has saved millions of lives around the world: a tremendous accomplishment in the face of disease. Vaccines remain one of the most effective life-preserving technologies that foundational biomedical research can produce, and Wistar continues our commitment to that mission. #nationalchildhealthday #childhealthday #vaccines

Protect yourself from the constant buzz of mosquitoes and the threat of malaria with WHO-recommended vaccines like R21 and RTS,S/AS01. We, at HCG Cancer Care, prioritize your health, because protecting you is our utmost concern.  #TogetherToWin #WorldMalariaDay #Vaccines #MalariaVaccine #WHO

A key challenge in developing a #malaria vaccine is choosing which stage of the infection to target. A new study reveals how transmission-blocking antigens make excellent targets for standalone or multi-stage vaccines https://pod.fo/e/26a3d1

On day 3 of #asv2024, CIVR-HRP's Engin Berber (Ross lab) presents “Pre-infection history with SARS-CoV-2 can affect long-term antibody immunity elicited by COVID-19 vaccines and IgG class switching.” If you miss the talk, find poster P28-52 for a second presentation. #meetCIVICs

Did you know that in just 5 decades, immunisation campaigns have enabled researchers to eradicate smallpox, nearly defeat polio, and ensure more children survive and thrive than ever before? This week, World Immunisation Week, aims to promote the importance of vaccines in protecting communities and saving lives. As a tech leader in the clinical trial industry, we're proud to partner with Sites, Sponsors, and CROs to bring next-generation vaccines to market. Let's band together against vaccine-preventable diseases. Contact us to learn how our innovative clinical trial recruitment solutions can help you reach 3.5 million vaccine patients: https://hubs.ly/Q02tLG8H0 #WorldImmunisationWeek #VaccinesSaveLives #VaccineResearch #ClinicalTrials #EvrimaTechnologies

Today we announced positive topline results from the Phase 1/2 study of VAX-31, our 31-valent pneumococcal conjugate vaccine (PCV) candidate, in healthy adults aged 50 and older. We are exceptionally proud to share these results, which we believe validate VAX-31’s potential as a best-in-class pneumococcal vaccine capable of raising the bar for immunogenicity standards. The public health community continues to highlight the need for broader-protection vaccines to prevent invasive pneumococcal disease, which is associated with high case-fatality rates, antibiotic resistance and meningitis. To address this need, VAX-31 was designed to increase coverage to more than 95% of IPD circulating in adults 50 and older in the United States, with the potential to provide significantly greater coverage relative to today’s standard-of-care adult PCVs. We want to extend a sincere thank you to everyone involved in this program, especially trial investigators, trial sites, study participants and the entire Vaxcyte team. For more, read the full press release here: #Vaccines #Biotechnology #ProtectHumankind #PCV